Thank you for this post. Really frustrating to see some posters feigning indignation at not getting P21 data when they know good and well they themselves cannot define what the relationship between P53 and P21 really signifies. Just read a few papers on P53 and it isn't hard to see how complicated those interactions are.
Excellent reply. Probably the best I've seen here in days. Very insightful, though looks to have been taken as insiteful.
See previous posts by people here on p21. It is not a simple biomarker. It's MOA is very poorly understood and it can in some cases be a contra-indication of anti-tumor activity. It has to be evaluated scientifically using conditional statistics, and will still not be conclusive. Kevetrin's efficacy will be proven on tumor and lesion progression, patient survival, QoL, etc, not p21. Seeing p21 increase simply means Kevetrin is "working" in a molecular sense. (Which is good; it can't be therapeutic without "working". But it can "work" and not be therapeutic. I hope people understand that.)